Holly McGuirk
Family · Pinehurst, NCNPI 1356913214
Payments from drug & device makers
Across 440 payments — averaging $26.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Sanofi$882
- Actelion Pharmaceuticals US, Inc.$802
- Takeda Pharmaceuticals U.S.A., Inc.$751
- Jazz Pharmaceuticals Inc.$625
- plus $6K from 33 others
What the payments were for
- Food & beverage$11,42598%
- Education$2072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$389
- OPSUMIT$389
- BREZTRI$375
- Inspire$358
- TYVASO$149
- REMODULIN$149
- ORENITRAM$149
- ACTHAR$144
- Arikayce$125
- CHARTIS CATHETER$125
- ZEPHYR DELIVERY CATHETER$125
- ZEPHYR ENDOBRONCHIAL VALVE$125
- PULMONX CHARTIS TABLET CONSOLE$125
- Prolastin-C Liquid$125
- Yupelri$125
- TRELEGY ELLIPTA$124
- NUCALA$124
How this compares
$11,632 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $218,691 |
| OpsumitMacitentan | 11 | $139,288 |
| Dupixent PenDupilumab | 28 | $107,872 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 132 | $102,173 |
| Breo ElliptaFluticasone/Vilanterol | 159 | $100,536 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $94,809 |
| Spiriva RespimatTiotropium Bromide | 35 | $25,338 |
| Advair HfaFluticasone Propion/Salmeterol | 60 | $20,172 |
| SymbicortBudesonide/Formoterol Fumarate | 71 | $18,643 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $16,878 |
| Arnuity ElliptaFluticasone Furoate | 43 | $11,835 |
| Fluticasone Propionate HfaFluticasone Propionate | 32 | $8,538 |
| DuleraMometasone/Formoterol | 26 | $8,504 |
| Qvar RedihalerBeclomethasone Dipropionate | 25 | $7,024 |
| AirsupraAlbuterol Sulfate/Budesonide | 12 | $5,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $604 | $244,02950 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,071 | $224,059315 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $802 | $139,28811 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Airsupra | $1,276 | $126,322215 claims |
| MerckDulera | $240 | $8,50426 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $7,02425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Pinehurst
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.